Abstract
A randomized, double-blind, placebo-controlled, parallel-group multicenter study was conducted to evaluate the antihypertensive efficacy and safety of 8-week treatment with one of three fixed-dose combinations—losartan 50 mg plus hydrochlorothiazide 12.5 mg, losartan 50 mg plus hydrochlorothiazide 6.25 mg, or losartan 25 mg plus hydrochlorothiazide 6.25 mg—in comparison with those of hydrochlorothiazide 12.5 mg alone, losartan 50 mg alone, or placebo in Japanese patients with essential hypertension. Significant reductions in sitting diastolic blood pressure (DBP) and systolic blood pressure (SBP) were seen in all three combination groups compared with the placebo group (each p<0.001). The greatest reductions in DBP and SBP were observed in the losartan 50 mg plus hydrochlorothiazide 12.5 mg group (12.7 and 18.0 mmHg, respectively). The reductions in the losartan 50 mg plus hydrochlorothiazide 12.5 mg group were significantly greater (each p<0.001) than those in the placebo group and each of the monotherapy groups. There were no significant differences in the incidences of clinical and laboratory drug-related adverse events between any of the combination groups and the placebo group. All combination groups showed improved hypokalemia and hyperuricemia compared to the hydrochlorothiazide 12.5 mg group. These results demonstrated that once-daily, fixed-dose combination therapy with losartan 50 mg plus hydrochlorothiazide 12.5 mg is well tolerated and more efficacious in lowering DBP and SBP than monotherapy in Japanese hypertensive patients.
Similar content being viewed by others
Article PDF
References
Whitworth JA, World Health Organization, International Society of Hypertension Writing Group: 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983–1992.
Collins R, Peto R, MacMahon S, et al: Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990; 335: 827–838.
Timmermans PBMWM, Carini DJ, Chiu AT, et al: Angiotensin II receptor antagonists. From discovery to antihypertensive drugs. Hypertension 1991; 18 ( Suppl 3): 136–142.
Carr AA, Prisant LM : Losartan: first of a new class of angiotensin antagonists for the management of hypertension. J Clin Pharmacol 1996; 36: 3–12.
Goodfriend TL, Elliott ME, Catt KJ : Angiotensin receptors and their antagonists. N Engl J Med 1996; 334: 1649–1654.
Goldberg AI, Dunlay MC, Sweet CS : Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 1995; 75: 793–795.
Weir MR, Elkins M, Liss C, Vrecenak AJ, Barr E, Edelman JM : Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension. Clin Ther 1996; 18: 411–428.
Oparil S, Barr E, Elkins M, Liss C, Vrecenak A, Edelman J : Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension. Clin Ther 1996; 18: 608–625.
Lacourciere Y, Brunner H, Irwin R, et al, Losartan Cough Study Group: Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertens 1994; 12: 1387–1393.
Brenner BM, Cooper ME, de Zeeuw D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–869.
Dahlöf B, Devereux RB, Kjeldsen SE, et al: Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995–1003.
Wright JM : Choosing a first-line drug in the management of elevated blood pressure: what is the evidence? 1: Thiazide diuretics. Can Med Assoc J 2000; 163: 57–60.
SHEP Cooperative Research Group: Prevention of stroke by atihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255–3264.
Dahlöf B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO : Morbidity and mortality in the Swedish trial in old patients with hypertension (STOP-Hypertension). Lancet 1991; 338: 1281–1285.
Chobanian AV, Bakris GL, Black HR, et al: Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC Report. JAMA 2003; 289: 2560–2572.
Japanese Society of Hypertension : Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004). Hypertens Res 2006; 29 ( Suppl): S1–S105.
Mori H, Yamamoto H, Saitou S, Hirano K, Yamauchi M, Umemura S : Current status of antihypertensive prescription and associated blood pressure control in Japan. Hypertens Res 2006; 29: 143–151.
Ohkubo T, Obara T, Funahashi J, et al: Control of blood pressure as measured at home and office, and comparison with physicians' assessment of control among treated hypertensive patients in Japan: First Report of the Japan Home versus Office Blood Pressure Measurement Evaluation (J-HOME) Study. Hypertens Res 2004; 27: 755–763.
Black HR, Elliott WJ, Neaton JD, et al: Baseline characteristics and early blood pressure control in the CONVINCE Trial. Hypertension 2001; 37: 12–18.
Guideline Committee : 2003 European Society of Hypertension—European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–1053.
Benedict CR : Safe and effective management of hypertension with fixed-dose combination therapy: focus on losartan plus hydrochlorothiazide. Int J Clin Pract 2000; 54: 48–54.
MacKay JH, Arcuri KE, Golgberg AI, Snapinn SM, Sweet CS : Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components. Arch Intern Med 1996; 156: 278–285.
Gradman AH, Brady WE, Gazdick LP, Lyle P, Zeldin RK : A multicenter, randomized, double-blind, placebo-controlled, 8-week trial of the efficacy and tolerability of once-daily losartan 100 mg/hydrochlorothiazide 25 mg and losartan 50 mg/hydrochlorothiazide 12.5 mg in the treatment of moderate-to-severe essential hypertension. Clin Ther 2002; 24: 1049–1061.
Flack JM, Saunders E, Gradman A, et al: Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension. Clin Ther 2001; 23: 1193–1208.
Fernández-Andrade C, Russo D, Iversen B, et al: Comparison of losartan and amlodipine in renally impaired hypertensive patients. Kidney Int Suppl 1998; 68: S120–S124.
Dickson TZ, Zagrobelny J, Lin CC, et al: Pharmacokinetics, safety, and antihypertensive efficacy of losartan in combination with hydrochlorothiazide in hypertensive patients with renal impairment. J Clin Pharmacol 2003; 43: 591–603.
Black HR : The evolution of low-dose diuretic therapy: the lessons from clinical trials. Am J Med 1996; 101 ( 3A): 47S–52S.
Soffer BA, Wright JT Jr, Pratt JH, Wiens B, Goldberg AI, Sweet CS : Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 1995; 26: 112–117.
Ruilope LM, Simpson RL, Toh J, Arcuri KE, Goldberg AI, Sweet CS : Controlled trial of losartan given concomitantly with different doses of hydrochlorothiazide in hypertensive patients. Blood Press 1996; 5: 32–40.
Nakashima M, Uematsu T, Kosuge K, Kanamaru M : Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 1992; 42: 333–335.
Enomoto A, Kimura H, Chairoungdua A, et al: Molecular identification of a renal urate-anion exchanger that regulates blood urate levels. Nature 2002; 417: 447–452.
Aurup P, Smith RD, Goldberg AI, Snavely D : Long-term blood pressure control with losartan alone or in combination with hydrochlorothiazide or other antihypertensive drugs in patients with mild to moderate essential hypertension. Am J Hypertens 1998; 11 ( Part 2): 110A ( Abstract).
Hansson L, Zanchetti A, Carruthers SG, et al, HOT Study Group: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755–1762.
Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al: A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy or patients with coronary artery disease. JAMA 2003; 290: 2805–2816.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Saruta, T., Ogihara, T., Matsuoka, H. et al. Antihypertensive Efficacy and Safety of Fixed-Dose Combination Therapy with Losartan plus Hydrochlorothiazide in Japanese Patients with Essential Hypertension. Hypertens Res 30, 729–739 (2007). https://doi.org/10.1291/hypres.30.729
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.30.729
Keywords
This article is cited by
-
Comparison of olmesartan combined with a calcium channel blocker or a diuretic in elderly hypertensive patients (COLM Study): safety and tolerability
Hypertension Research (2015)
-
The Comparative Efficacy and Safety of the Angiotensin Receptor Blockers in the Management of Hypertension and Other Cardiovascular Diseases
Drug Safety (2015)
-
Losartan/hydrochlorothiazide combination vs. high-dose losartan in patients with morning hypertension—a prospective, randomized, open-labeled, parallel-group, multicenter trial
Hypertension Research (2012)
-
Mechanism underlying the efficacy of combination therapy with losartan and hydrochlorothiazide in rats with salt-sensitive hypertension
Hypertension Research (2011)
-
One-year effectiveness and safety of open-label losartan/hydrochlorothiazide combination therapy in Japanese patients with hypertension uncontrolled with ARBs or ACE inhibitors
Hypertension Research (2010)